“In the blue sky scenario, this could become the world’s best- selling drug as the indication is so broad,” he said. “It has a path to revenues that we rarely ever see from a pharma product.”

Oh, the blue sky scenario. I’m no stranger to it myself - I love the blue sky scenario. But how often does it ever descend to earth? It’s not going to do it this time. Sanofi-Aventis was reduced to making the suggestion that every potential patient be first screened for depression, which doesn’t sound like the sort of iron wrecking ball that usually gets welded to the world’s best-selling drugs.

In the wake of this development disaster, here are a few points that may not get the attention they deserve: first, consider the money that S-A has spent on this drug. We’re never going to be shown an accurate accounting; no one outside the upper reaches of the company will ever see that. But I seriously doubt if they’ve ever spent more on any program. There’s an excellent chance that most of it will never be recovered, not by rimonabant - it’ll have to be recovered by whatever drugs the company can come up with in the future. They’ll be priced accordingly.

Second, think about the position of their competitors. All sorts of companies have pursued this wonder blockbuster opportunity. If you run CB-1 antagonists through the databases, all kinds of stuff comes hosing out. Merck and Pfizer are the companies that were most advanced - you don’t get much more advanced than Phase III clinical trials - but plenty of others spent time and money on the chase. All of those prospects have taken grievous damage. Odds are that rimonbant’s problems are mechanism-related, and proving otherwise will be an expensive job. This is something to consider when you next hear about all those easy, cheap me-too drugs.

Rimonabant Acomplia Taranabant

How to use
One 20mg capsule, with a glass of water, or as directed by your doctor, once a day, before breakfast. Never increase your dose, take it more frequently or use it for a longer period of time than prescribed because this drug can be habit-forming. This medication will only work in conjunction with a calorie controlled diet and exercise plan.

Buy Rimonabant

Side effects
All drugs have side effects, and Rimonabant is no exception. Some of the side effects are beneficial - such as the altered blood lipid profile. However, there are other known side effects that may influence whether or not you continue to take the drug. These include:
Nausea and vomiting.
Nausea, vomiting and other gastrointestinal disorders are relatively common side effects of taking Acomplia.
Disorders of the nervous system - including headaches, faintness and dizziness.
Psychiatric disorders including mood swings, anxiety, depression, irritability, sleep disorders and other similar disorders.
If you already have a history of mental health disorders, it would be highly advisable to mention this to your doctor before obtaining this drug.
Buy Rimonabant

Precautions
Rimonabant should only under your doctor’s guidance. It should not be taken by:
Anyone who exhibits hypersensitivity or an allergic reaction to the drug.
Anyone with impaired or limited liver function.
Anyone with impaired kidney function. It should never be used in patients with a severely limited kidney function.
Anyone over the age of 75, or anyone under the age of 18 years.
Pregnant or lactating women - safety in these groups has not been established.
Anyone suffering from epilepsy the medication should be prescribed with caution in this instance.
The Rimonabant tablet contains lactose and should therefore not be prescribed to patients with lactose intolerance.
It should not be prescribed to patients with an uncontrolled psychiatric condition, and is not recommended for use with antidepressants.
Buy Rimonabant
Drug interactions
Rimonabant should not be taken, or should be taken only under exceptional circumstances, under your doctor’s direct guidance, in the following circumstances:

Buy Rimonabant

1. Anyone who exhibits hypersensitivity or an allergic reaction to the drug (it should never be used in these circumstances).
2. It should only be used with caution in combination with CYP3A4 inhibitors, such as ketocinazole, ritonavir, clarthromycin and related drugs.
3. It should not be prescribed to patients with an uncontrolled psychiatric condition, and is not recommended for use with antidepressants.

Overdose
If overdose is suspected, contact your local poison control center or emergency room immediately.

Notes
Do not share this medication with others. This medication should be used in addition to a reduced calorie diet. Blood pressure and pulse may be measured and laboratory tests performed to monitor side effects.

Missed dose
If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

Storage
Store at room temperature between 59 and 86 degrees F (15-30 degrees C) away from light and moisture. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Important note
The above information is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other health care professional. It should not be construed that taking this medication is safe, appropriate or effective for you.

Buy Rimonabant

News:

Weight-Loss Drug Helps Patients Burn Fat While Resting.

CHICAGO — A new weight loss drug is under study, and the early results are promising.

A study funded by drug manufacturer Merck finds the experimental drug Taranabant helped obese patients lose weight and burn calories while resting.

The 12-week study looked at 533 obese patients who took different doses of the drug. They found all doses spurred some weight loss — those taking the highest dose dropped the most pounds.

However, the higher the dosage the greater the risk for side effects; some participants experienced nausea, vomiting and increased irritability.

A similar drug under the came Acomplia is on the market in Europe. Manufacturers have applied for approval, but an expert panel did not recommend the drug due to safety concerns.

This is a phase-two study, meaning the drug won’t be available, if at all, for many years.